Forty Seven Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Forty Seven Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
Forty Seven presents a practical BD-screening case because its returned pipeline contains 1 records and the deal search returned 2 transaction records. The lead returned asset is FSI-174, associated with c-Kit and Hematologic Neoplasms, at Preclinical. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | FSI-174 | Forty Seven LLC | Preclinical | Pipeline record: c-Kit; Hematologic Neoplasms. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Gilead to Acquire Forty Seven for $4.9 Billion | Preclinical asset with c-Kit exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2020-03-02 | Gilead to Acquire Forty Seven for $4.9 Billion | Active | total_amount: 4900; disclosed: false |
| 2019-07-10 | Ono collaborates with Forty to develop, manufacture, and market 5F9 and other CD47 antibodies in Japan, South Korea, Taiwan, and the ASEAN countries. | Active | upfront_payment: 15.8; milestone_payment: 104; total_amount: 119.8; disclosed: true |
The most relevant returned precedent is: Gilead to Acquire Forty Seven for $4.9 Billion (2020-03-02). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- Lifeway Foods, Inc. - 2025 Quarterly report: Lifeway Foods, Inc. - 2025 Quarterly report Liquidity and Capital Resources Management assesses the Company’s liquidity in terms of its ability to generate cash to fund its operating, investing, and financing activities. The Company remains in a strong financial position, and believes that its cash flow from operations, revolving credit facility, and cash and cash equivalents will continue to provide sufficient liquidity for its working capital needs, capital resource requirements, and growth initiatives and to ensure the continuation of the Company as a going concern. If additional borrowings are needed, $25,000 was available under the Revolving Credit Facility as of March 31, 2025 (see Note 7, Debt). We are in compliance with the terms of the Credit Agreement and expect to meet foreseeab
- AIR WATER INC. - Annual securities report-20th Period(2019.04.01-2020.03.31): AIR WATER INC. - Annual securities report-20th Period(2019.04.01-2020.03.31) ③资本の财源及び资金の流动性に系る情报 なお、资金の机动的かつ安定的な调达に向け、2020年３月に取引银行３行との间に総额200亿円のシンジケーショ ン方式によるコミットメントライン契约を缔结しました。 成长投资については、経済活动の停滞が长期化した局面に备えて十分な财务の安全性を维持するため、今后の Ｍ＆Ａ投资および设备投资は、事业环境の変化を慎重に见极めながら厳选していきます。 株主还元については、配当性向の目标を亲会社所有者に帰属する当期利益の30％としており、中长期的な成长の ための戦略的投资等に必要な内部留保の充実に留意しつつ、将来にわたって业绩に见合った安定的な配当を行うこ とを基本方针としております。 (4) 重要な会计上の见积り及び当该见积りに用いた仮定 当社グループの连结财务诸表は、IFRSに基づいて作成しております。この连结财务诸表の作成にあたって、経営 者による会计方针の选択・适用、资产・负债及び収益・费用の报告金额及び开示に影响を与える见积りを必要とし ております。経営者は、これらの见积りについて、过去の実绩や现状を勘案し合理的に判断しておりますが、実际 の结果は、见积り特有の不确実性があるため、これらの见积りと异なる场合があります。
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether Forty Seven is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
Forty Seven merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate FSI-174, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
